Comprehensive Stock Comparison
Compare Puma Biotechnology, Inc. (PBYI) vs Genmab A/S (GMAB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | GMAB | 30.7% revenue growth vs PBYI's -0.9% |
| Value | PBYI | Lower P/E (22.8x vs 23.2x) |
| Quality / Margins | GMAB | 46.8% net margin vs PBYI's 13.6% |
| Stability / Safety | PBYI | Beta 0.54 vs GMAB's 0.61 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PBYI | +59.2% vs GMAB's +29.8% |
| Efficiency (ROA) | GMAB | 93.6% ROA vs PBYI's 14.4%, ROIC 22.2% vs 24.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing targeted cancer therapies, primarily for HER2-positive breast cancer. It generates revenue through sales of its FDA-approved drug neratinib (marketed as NERLYNX) and licensing agreements with pharmaceutical partners worldwide. The company's moat lies in its specialized expertise in HER2-targeted oncology and its patent-protected neratinib franchise, which addresses a specific niche in breast cancer treatment.
Genmab is a biotechnology company that develops and commercializes antibody-based therapies for cancer and other serious diseases. It generates revenue primarily through product sales of its marketed antibodies like DARZALEX and teprotumumab, plus significant royalties and milestone payments from partnerships with pharmaceutical companies like Johnson & Johnson. The company's key advantage is its proprietary antibody technology platforms — particularly its DuoBody bispecific antibody platform — which enable it to create differentiated therapies with improved efficacy and safety profiles.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PBYI leads in 2 of 6 categories (Valuation Metrics, Total Returns). GMAB leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
GMAB is the larger business by revenue, generating $14.0B annually — 61.5x PBYI's $228M. GMAB is the more profitable business, keeping 46.8% of every revenue dollar as net income compared to PBYI's 13.6%. On growth, PBYI holds the edge at +27.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PBYIPuma Biotechnolog… | GMABGenmab A/S |
|---|---|---|
| RevenueTrailing 12 months | $228M | $14.0B |
| EBITDAEarnings before interest/tax | $46M | $5.3B |
| Net IncomeAfter-tax profit | $31M | $6.6B |
| Free Cash FlowCash after capex | $48M | $2.9B |
| Gross MarginGross profit ÷ Revenue | +74.5% | +94.3% |
| Operating MarginEBIT ÷ Revenue | +16.3% | +36.2% |
| Net MarginNet income ÷ Revenue | +13.6% | +46.8% |
| FCF MarginFCF ÷ Revenue | +21.2% | +20.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.8% | -81.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -33.3% | -66.7% |
Valuation Metrics
At 9.3x trailing earnings, PBYI trades at a 39% valuation discount to GMAB's 15.4x P/E. On an enterprise value basis, PBYI's 7.7x EV/EBITDA is more attractive than GMAB's 14.9x.
| Metric | PBYIPuma Biotechnolog… | GMABGenmab A/S |
|---|---|---|
| Market CapShares × price | $287M | $18.1B |
| Enterprise ValueMkt cap + debt − cash | $286M | $16.7B |
| Trailing P/EPrice ÷ TTM EPS | 9.34x | 15.36x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.80x | 23.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.53x |
| EV / EBITDAEnterprise value multiple | 7.67x | 14.90x |
| Price / SalesMarket cap ÷ Revenue | 1.26x | 5.34x |
| Price / BookPrice ÷ Book value/share | 2.22x | 3.28x |
| Price / FCFMarket cap ÷ FCF | 6.89x | 15.15x |
Profitability & Efficiency
GMAB delivers a 114.2% return on equity — every $100 of shareholder capital generates $114 in annual profit, vs $24 for PBYI. GMAB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PBYI's 0.22x. On the Piotroski fundamental quality scale (0–9), PBYI scores 7/9 vs GMAB's 5/9, reflecting strong financial health.
| Metric | PBYIPuma Biotechnolog… | GMABGenmab A/S |
|---|---|---|
| ROE (TTM)Return on equity | +23.8% | +114.2% |
| ROA (TTM)Return on assets | +14.4% | +93.6% |
| ROICReturn on invested capital | +24.7% | +22.2% |
| ROCEReturn on capital employed | +29.6% | +18.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.22x | 0.03x |
| Net DebtTotal debt minus cash | -$1M | -$8.8B |
| Cash & Equiv.Liquid assets | $30M | $9.9B |
| Total DebtShort + long-term debt | $29M | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | 5.49x | 48.21x |
Total Returns (with DRIP)
A $10,000 investment in GMAB five years ago would be worth $8,383 today (with dividends reinvested), compared to $5,583 for PBYI. Over the past 12 months, PBYI leads with a +59.2% total return vs GMAB's +29.8%. The 3-year compound annual growth rate (CAGR) favors PBYI at 13.9% vs GMAB's -7.8% — a key indicator of consistent wealth creation.
| Metric | PBYIPuma Biotechnolog… | GMABGenmab A/S |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | -7.5% |
| 1-Year ReturnPast 12 months | +59.2% | +29.8% |
| 3-Year ReturnCumulative with dividends | +47.7% | -21.6% |
| 5-Year ReturnCumulative with dividends | -44.2% | -16.2% |
| 10-Year ReturnCumulative with dividends | -87.3% | +138.4% |
| CAGR (3Y)Annualised 3-year return | +13.9% | -7.8% |
Risk & Volatility
PBYI is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than GMAB's 0.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GMAB currently trades 83.1% from its 52-week high vs PBYI's 74.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PBYIPuma Biotechnolog… | GMABGenmab A/S |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.61x |
| 52-Week HighHighest price in past year | $7.68 | $35.43 |
| 52-Week LowLowest price in past year | $2.58 | $17.24 |
| % of 52W HighCurrent price vs 52-week peak | +74.2% | +83.1% |
| RSI (14)Momentum oscillator 0–100 | 69.9 | 38.3 |
| Avg Volume (50D)Average daily shares traded | 343K | 1.5M |
Analyst Outlook
Wall Street rates PBYI as "Buy" and GMAB as "Buy".
| Metric | PBYIPuma Biotechnolog… | GMABGenmab A/S |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $40.50 |
| # AnalystsCovering analysts | 19 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.5% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | 100 | 63.8 | -36.2% |
| Genmab A/S (GMAB) | 100 | 138.39 | +38.4% |
Genmab A/S (GMAB) returned -16% over 5 years vs Puma Biotechnology,… (PBYI)'s -44%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | $0.00 | $228M | — |
| Genmab A/S (GMAB) | $1.8B | $21.5B | +1085.3% |
Puma Biotechnology, Inc.'s revenue grew from $0M (2016) to $228M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | -10.5% | 13.6% | +229.2% |
| Genmab A/S (GMAB) | 65.4% | 36.4% | -44.3% |
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | 208.4 | 9.8 | -95.3% |
| Genmab A/S (GMAB) | 9.3 | 1.7 | -81.7% |
Puma Biotechnology, Inc. has traded in a 5x–208x P/E range over 4 years; current trailing P/E is ~9x. Genmab A/S has traded in a 2x–9x P/E range over 8 years; current trailing P/E is ~15x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | -8.29 | 0.61 | +107.4% |
| Genmab A/S (GMAB) | 1.92 | 12.14 | +532.3% |
Puma Biotechnology, Inc.'s EPS grew from $-8.29 (2016) to $0.61 (2025).
Chart 6Free Cash Flow — 5 Years
Puma Biotechnology, Inc. generated $42M FCF in 2025 (+102% vs 2021). Genmab A/S generated $8B FCF in 2024 (+284% vs 2021).
PBYI vs GMAB: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is PBYI or GMAB a better buy right now?
Puma Biotechnology, Inc. (PBYI) offers the better valuation at 9.3x trailing P/E (22.8x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PBYI or GMAB?
On trailing P/E, Puma Biotechnology, Inc. (PBYI) is the cheapest at 9.3x versus Genmab A/S at 15.4x. On forward P/E, Puma Biotechnology, Inc. is actually cheaper at 22.8x.
03Which is the better long-term investment — PBYI or GMAB?
Over the past 5 years, Genmab A/S (GMAB) delivered a total return of -16.2%, compared to -44.2% for Puma Biotechnology, Inc. (PBYI). A $10,000 investment in GMAB five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: GMAB returned +138.4% versus PBYI's -87.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PBYI or GMAB?
By beta (market sensitivity over 5 years), Puma Biotechnology, Inc. (PBYI) is the lower-risk stock at 0.54β versus Genmab A/S's 0.61β — meaning GMAB is approximately 13% more volatile than PBYI relative to the S&P 500. On balance sheet safety, Genmab A/S (GMAB) carries a lower debt/equity ratio of 3% versus 22% for Puma Biotechnology, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — PBYI or GMAB?
Genmab A/S (GMAB) is the more profitable company, earning 36.4% net margin versus 13.6% for Puma Biotechnology, Inc. — meaning it keeps 36.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 31.1% versus 16.3% for PBYI. At the gross margin level — before operating expenses — GMAB leads at 95.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is PBYI or GMAB more undervalued right now?
On forward earnings alone, Puma Biotechnology, Inc. (PBYI) trades at 22.8x forward P/E versus 23.2x for Genmab A/S — 0.4x cheaper on a one-year earnings basis.
07Which pays a better dividend — PBYI or GMAB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is PBYI or GMAB better for a retirement portfolio?
For long-horizon retirement investors, Genmab A/S (GMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.61), +138.4% 10Y return). Both have compounded well over 10 years (GMAB: +138.4%, PBYI: -87.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between PBYI and GMAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.